Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathleen G. Essel"'
Autor:
Jessica M. Gillen, Sarah C. Grimes, Kathleen G. Essel, Grace E. Duininck, Daniel Zhao, John S. Thompson, Debra L. Richardson
Publikováno v:
Gynecologic Oncology Reports, Vol 34, Iss , Pp 100660- (2020)
We aimed to evaluate how the need for social services programs is associated with outcomes amongst patients with cervical cancer undergoing chemoradiation with a single institution, retrospective analysis of patients from January 1, 2015-July 31, 201
Externí odkaz:
https://doaj.org/article/489172b5587d4a11bf0aad2b86b567c2
Autor:
K. Peng, Stacy A. Smrz, Monica Hagan Vetter, Alexander B. Olawaiye, Paola A. Gehrig, W.H. Gotlieb, Keitaro Matsuo, Laura L. Holman, Shitanshu Uppal, Kathleen G Essel, Kristin Bixel, Laurie L. Brunette, M.P. Cisa, A. Stuart Staley, Stephen L. Rose, B.F. Lees, Ester Goldfeld, Robert W. Holloway, Brittany A. Davidson, Katherine L. Tucker
Publikováno v:
Gynecologic Oncology. 159:354-358
The objective of this study was to assess the rate of discordance between clinical and pathologic tumor size for women with stage IB1 cervical cancer (FIGO 2009 criteria), assess risk factors for discordance, and determine the impact of discordance o
Autor:
B.F. Lees, Walter H. Gotlieb, Katherine L. Tucker, Alexander B. Olawaiye, Robert W. Holloway, M Paige Cisa, K. Peng, Brittany A. Davidson, Kristin Bixel, Laurie L. Brunette, Stephen L. Rose, Shitanshu Uppal, Koji Matsuo, Laura L. Holman, Monica Hagan Vetter, Paola A. Gehrig, Ester Goldfeld, A. Staley, Kathleen G Essel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(10)
PURPOSE To compare the disease-free survival (DFS) between open and minimally invasive radical hysterectomies (RH) performed in academic medical institutions METHODS Retrospective multi-institutional review of patients undergoing RH for stage IA1 (wi
Autor:
Kathleen G Essel, Kathleen N. Moore
Publikováno v:
Expert Review of Anticancer Therapy. 18:727-733
Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast c
Autor:
Jubilee Brown, Amanda S. Bruegl, Kathleen G Essel, L.K. Drury, David M. Gershenson, Aaron Shafer, Lois M. Ramondetta, R. Wendel Naumann
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 28(8)
ObjectiveThe aim of this study was to determine the utility of surgery in patients with gestational trophoblastic neoplasia (GTN).Materials and MethodsWe performed a retrospective institutional review board–approved analysis of all patients with GT